Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-478701

RESUMO

Coronavirus-induced disease 19 (COVID-19) infects more than three hundred and sixty million patients worldwide, and people with severe symptoms frequently die of acute respiratory distress syndrome (ARDS). Autopsy demonstrates the presence of thrombosis and microangiopathy in the small vessels and capillaries. Recent studies indicated that excessive neutrophil extracellular traps (NETs) contributed to immunothrombosis, thereby leading to extensive intravascular coagulopathy and multiple organ dysfunction. Thus, understanding the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced NET formation would be helpful to reduce thrombosis and prevent ARDS. It has been shown that sera from individuals with COVID-19 triggered NET release in vitro, and spleen tyrosine kinase (Syk) inhibitor R406 inhibited NETosis caused by COVID-19 plasma. However, the serum components responsible for NET formation are still unknown. In this study, we found that virus-free extracellular vesicles (EVs) from COVID-19 patients (COVID-19 EVs) induced robust NET formation via Syk-coupled C-type lectin member 5A (CLEC5A). Blockade of CLEC5A inhibited COVID-19 EVs-induced NETosis, and simultaneous blockade of CLEC5A and TLR2 further suppressed SARS-CoV-2-induced NETosis in vitro. Moreover, thromboinflammation and lung fibrosis were attenuated dramatically in clec5a-/-/tlr2-/- mice. These results suggest that COVID-19 EVs play critical roles in SARS-CoV-2-induced immunothrombosis, and blockade of CLEC5A and TLR2 is a promising strategy to inhibit SARS-CoV-2-induced intravascular coagulopathy and reduce the risk of ARDS in COVID-19 patients.

2.
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-478406

RESUMO

The emerging SARS-CoV-2 variants of concern (VOC) harbor mutations associated with increasing transmission and immune escape, hence undermine the effectiveness of current COVID-19 vaccines. In late November of 2021, the Omicron (B.1.1.529) variant was identified in South Africa and rapidly spread across the globe. It was shown to exhibit significant resistance to neutralization by serum not only from convalescent patients, but also from individuals receiving currently used COVID-19 vaccines with multiple booster shots. Therefore, there is an urgent need to develop next generation vaccines against VOCs like Omicron. In this study, we develop a panel of mRNA-LNP-based vaccines using the receptor binding domain (RBD) of Omicron and Delta variants, which are dominant in the current wave of COVID-19. In addition to the Omicron- and Delta-specific vaccines, the panel also includes a "Hybrid" vaccine that uses the RBD containing all 16 point-mutations shown in Omicron and Delta RBD, as well as a bivalent vaccine composed of both Omicron and Delta RBD-LNP in half dose. Interestingly, both Omicron-specific and Hybrid RBD-LNP elicited extremely high titer of neutralizing antibody against Omicron itself, but few to none neutralizing antibody against other SARS-CoV-2 variants. The bivalent RBD-LNP, on the other hand, generated antibody with broadly neutralizing activity against the wild-type virus and all variants. Surprisingly, similar cross-protection was also shown by the Delta-specific RBD-LNP. Taken together, our data demonstrated that Omicron-specific mRNA vaccine can induce potent neutralizing antibody response against Omicron, but the inclusion of epitopes from other variants may be required for eliciting cross-protection. This study would lay a foundation for rational development of the next generation vaccines against SARS-CoV-2 VOCs.

3.
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-454910

RESUMO

COVID-19 in humans is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that belongs to the beta family of coronaviruses. SARS-CoV-2 causes severe respiratory illness in 10-15% of infected individuals and mortality in 2-3%. Vaccines are urgently needed to prevent infection and to contain viral spread. Although several mRNA- and adenovirus-based vaccines are highly effective, their dependence on the "cold chain" transportation makes global vaccination a difficult task. In this context, a stable lyophilized vaccine may present certain advantages. Accordingly, establishing additional vaccine platforms remains vital to tackle SARS- CoV-2 and any future variants that may arise. Vaccinia virus (VACV) has been used to eradicate smallpox disease, and several attenuated viral strains with enhanced safety for human applications have been developed. We have generated two candidate SARS-CoV-2 vaccines based on two vaccinia viral strains, MVA and v-NY, that express full-length SARS-CoV-2 spike protein. Whereas MVA is growth-restricted in mammalian cells, the v-NY strain is replication-competent. We demonstrate that both candidate recombinant vaccines induce high titers of neutralizing antibodies in C57BL/6 mice vaccinated according to prime-boost regimens. Furthermore, our vaccination regimens generated TH1-biased immune responses in mice. Most importantly, prime-boost vaccination of a Syrian hamster infection model with MVA-S and v-NY-S protected the hamsters against SARS-CoV-2 infection, supporting that these two vaccines are promising candidates for future development. Finally, our vaccination regimens generated neutralizing antibodies that partially cross-neutralized SARS-CoV-2 variants of concern.

4.
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-425674

RESUMO

The COVID-19 pandemic presents an unprecedented challenge to global public health. Rapid development and deployment of safe and effective vaccines are imperative to control the pandemic. In the current study, we applied our adjuvanted stable prefusion SARS-CoV-2 spike (S-2P)-based vaccine, MVC-COV1901, to hamster models to demonstrate immunogenicity and protection from virus challenge. Golden Syrian hamsters immunized intramuscularly with two injections of 1 {micro}g or 5 {micro}g of S-2P adjuvanted with CpG 1018 and aluminum hydroxide (alum) were challenged intranasally with SARS-CoV-2. Prior to virus challenge, the vaccine induced high levels of neutralizing antibodies with 10,000-fold higher IgG level and an average of 50-fold higher pseudovirus neutralizing titers in either dose groups than vehicle or adjuvant control groups. Six days after infection, vaccinated hamsters did not display any weight loss associated with infection and had significantly reduced lung pathology and most importantly, lung viral load levels were reduced to lower than detection limit compared to unvaccinated animals. Vaccination with either 1 g or 5 g of adjuvanted S-2P produced comparable immunogenicity and protection from infection. This study builds upon our previous results to support the clinical development of MVC-COV1901 as a safe, highly immunogenic, and protective COVID-19 vaccine.

5.
Chinese Journal of Biotechnology ; (12): 2357-2366, 2020.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-878492

RESUMO

Antigenic purity is important for quality control of the foot-and-mouth (FMD) whole virus inactivated vaccine. The recommended method for evaluation the antigenic purity of FMD vaccine is to check the serum conversion to non-structural protein (NSP) 3AB antibody after 2 to 3 times inoculation of animals with inactivated vaccine. In this study, we developed a quantitative ELISA to detect the amount of residual 3AB in vaccine antigen, to provide a reference to evaluate the antigenic purity of FMD vaccine. Monoclonal antibody (Mab) of NSP 3A and HRP-conjugated Mab of NSP 3B were used to establish a sandwich ELISA to quantify the NSP 3AB in vaccine antigen of FMD. Purified NSP 3AB expressed in Escherichia coli was serially diluted and detected to draw the standard curve. The detectable limit was determined to be the lowest concentration of standard where the ratio of its OD value to OD blank well was not less than 2.0. Results: The OD value was linearly corelated with the concentration of 3AB protein within the range between 4.7 and 600 ng/mL. The correlation coefficient R² is greater than 0.99, and the lowest detectable limit is 4.7 ng/mL. The amount of 3AB protein in non-purified inactivated virus antigen was detected between 9.3 and 200 ng/mL depending on the 12 different virus strains, whereas the amount of 3AB in purified virus antigen was below the lowest detectable limit. The amount of 3AB in 9 batches of commercial FMD vaccine antigens was between 9.0 and 74 ng/mL, whereas it was below the detectable limit in other 24 batches of commercial vaccine antigens. Conclusion: the sandwich ELISA established in this study is specific and sensitive to detect the content of 3AB protein in vaccine antigen of FMD, which will be a useful method for evaluation of the antigenic purity and quality control of FMD inactivated vaccine.


Assuntos
Animais , Anticorpos Antivirais , Ensaio de Imunoadsorção Enzimática , Febre Aftosa/prevenção & controle , Vírus da Febre Aftosa , Proteínas não Estruturais Virais/genética , Vacinas Virais
6.
China Pharmacy ; (12): 980-984, 2019.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-817026

RESUMO

OBJECTIVE: To evaluate risk factors of linezolid-induced thrombocytopenia systematically, and to provide reference for rational drug use in clinic. METHODS: Retrieved from PubMed, Embase, Cochrane library, Web of Science, CBM, CNKI and Wanfang database, during database establishment to Oct. 2018, clinical studies about risk factors of linezolid-induced thrombocytopenia were collected, and the data of literatures met criteria were collected. After Newcastle-Ottawa scale (NOS) was applied for evaluating the quality of included literatures. Meta-analysis was conducted by using Rev Man 5.3 software. RESULTS: Sixteen clinical studies involving 2 264 patients in total were included. Results of Meta-analysis showed that daily per kg dose (DKPD) [SMD=0.62, 95%CI(0.29,0.95), P=0.000 2], low platelet count before medication [SMD=-0.90, 95%CI(-1.62, -0.18), P=0.01], low creatinine clearance rate [SMD=-0.65, 95%CI(-1.10,-0.19), P=0.005], long treatment course [SMD=0.45, 95%CI(0.18,0.71), P=0.000 9], low body weight  [SMD=-0.36, 95%CI(-0.60,-0.11),P=0.005] significantly influenced the occurrence of thrombocytopenia. CONCLUSIONS: The risk factors associated with linezolid-induced thrombocytopenia include low baseline platelet count, low creatinine clearance rate, low body weight, long medication course and high DKPD.

7.
National Journal of Andrology ; (12): 129-134, 2019.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-816848

RESUMO

Objective@#To explore the relationship of sperm DNA fragmenation index (DFI) with semen parameters and assess its application value in the evaluation of semen quality.@*METHODS@#A total of 9 694 semen samples were collected and examined for sperm DFI and high DNA stainability (HDS) by flow cytometry-assisted sperm chromatin structure analysis (SCSA). According to the WHO Laboratory Manual for the Examination and Processing of Human Semen (5th Ed), the samples were divided into a normal group and abnormal groups A (sperm concentration [SC]: [11.3-14.0] ×10⁶/ml, total sperm motility [TSM]: 30%-39%, progressively motile sperm [PMS]: 24%-31%), B (SC: [7.5-11.2] ×10⁶/ml, TSM: 20%-29%, PMS: 16%-23%), C (SC: [3.8-7.4] ×10⁶/ml, TSM: 10%-,19% PMS: 8%-15%) and D (SC: [0-3.7]×10⁶/ml, TSM: 0-9%, PMS: 0-7%), and also into three sperm DFI groups (DFI 30%). The correlation between sperm DFI and seminal parameters was analyzed by Pearson correlation and multiple linear regression analyses.@*RESULTS@#DFI was dramatically lower in the normal than in the abnormal groups (P < 0.01), and increased in proportion to the decrease of semen parameters in the abnormal groups A, B, C and D (P < 0.01). Pearson correlation analysis showed that DFI was correlated positively with age (r = 0.15, P < 0.01), abstinence time (r = 0.10, P < 0.01), semen volume (r = 0.05, P < 0.01) and HDS (r = 0.15, P < 0.01), but negatively with semen pH (r = -0.06, P < 0.01), SC (r = -0.27, P < 0.01), TSM (r = -0.53, P < 0.01), PMS (r = -0.52, P < 0.01) and morphologically normal sperm (r = -0.16, P < 0.01). Multiple linear regression analysis revealed that TSM, SC, age, abstinence time and semen pH were five important variables associated with DFI, with standardized regression coefficients of -0.47, -0.19, 0.12, 0.07, and -0.04, respectively (all P < 0.01).@*CONCLUSIONS@#There is a moderate correlation between sperm DFI and semen parameters, which can be used synergistically for the assessment of semen quality.

8.
China Pharmacy ; (12): 547-552, 2018.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-704625

RESUMO

OBJECTIVE: To systematically evaluate the relationship between rituximab and the occurence of pneumonia, and to provide evidenle-based reference in clinic. METHODS: Retrieved from PubMed, Embase, Cochrane Library, Web of Science, CBM, CNKI, Wanfang database and other database, RCTs, quasi-RCTs, controlled clinical trials were searched from inception to Mar. 2017. After literature screening, data extraction, literature quality evaluation and analysis of bias risk referring to Cochrane Intervention Measure System Evaluation Manual (5. 3 edition), Meta-analysis was conducted by using RevMan 5. 3 software. RESULTS: A total of 16 literatures were finally included, consisting of 14 RCTs and 1 386 patients. The results of Meta-analysis showed that the incidence of rituximab associated pneumonia in observation group was lower than control group, but without statistical significance [OR=1. 19, 95% CI (0. 75, 1. 91), Z=0. 74, P=0. 46]. Subgroup analysis was conducted according to sample size, multiple-center, intervention dose, there was no statistical significance in the incidence of rituximab-associated pneumonia between 2 groups (P>0. 05). CONCLUSIONS: There was no significant difference in the incidence of pneumonia between observation group and control group, rituximab is not associated with the occurrence of pneumonia. Due to methodology limit of included studies, most of high quality long-term follow-up studies have not been included. Large-scale and high quality clinical studies are required for further valuation.

9.
Chinese Medical Journal ; (24): 2129-2133, 2013.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-273024

RESUMO

<p><b>BACKGROUND</b>To evaluate the safety of intracytoplasmic sperm injection (ICSI) with epididymal or testicular sperm, this study compared children born after ICSI treatment with epididymal or testicular sperm with children conceived after ICSI with ejaculated sperm.</p><p><b>METHODS</b>This retrospective study included 317 children born after ICSI with percutaneous epididymal sperm aspiration (PESA), 103 children born after ICSI with testicular sperm aspiration (TESA), and a control group of 1008 children born after ICSI with ejaculated sperm. All of the patients received their assisted reproductive treatment in the Reproductive Medicine Center of the First Affiliated Hospital of Zhengzhou University from January 2004 to December 2011. Data, such as the rate of stillbirths, perinatal mortality, gestational age, birth weight, and the rate of congenital malformations of the three groups, were compared.</p><p><b>RESULTS</b>PESA and TESA children were not different from ICSI children in the rate of stillbirths, perinatal mortality, infant mortality rate, gestational age, the rate of prematurity, and the rate of malformations (P > 0.05). A slight increase in birth defects was reported in the TESA group compared with those in the control group, but there was no significant difference between the groups (P > 0.05).</p><p><b>CONCLUSION</b>ICSI with epididymal or testicular sperm does not lead to more stillbirths or congenital malformations compared with ICSI using ejaculated sperm.</p>


Assuntos
Adulto , Feminino , Humanos , Recém-Nascido , Masculino , Gravidez , Anormalidades Congênitas , Epidemiologia , Epididimo , Morte Fetal , Epidemiologia , Seguimentos , Estudos Retrospectivos , Injeções de Esperma Intracitoplásmicas
10.
National Journal of Andrology ; (12): 522-526, 2012.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-286469

RESUMO

<p><b>OBJECTIVE</b>To investigate whether the day of embryo transfer (day 2 or day 3) affects clinical pregnancy outcomes in poor responder patients.</p><p><b>METHODS</b>We retrospectively analyzed the pregnancy rates of 265 initial fresh cycles of in vitro fertilization-embryo transfer (IVF-ET), all transferred on day 2 (n = 169) or day 3 (n = 96) irrespective of quality because of an extremely low number of available embryos.</p><p><b>RESULTS</b>Among the poor responders aged < 35 years, a higher rate of clinical pregnancy was achieved in the day-3 than in the day-2 group (50% vs 32.43% ; RR = 0.65, 95% CI: 0.43 - 0.99), and among those aged years, the two groups showed similar pregnancy outcomes.</p><p><b>CONCLUSION</b>Shortening the time of embryo culture has no obvious benefit for the pregnancy outcome. For the poor responders under 35 years of age, day-3 embryo transfer may afford an even higher rate of clinical pregnancy.</p>


Assuntos
Adulto , Feminino , Humanos , Gravidez , Transferência Embrionária , Métodos , Fertilização in vitro , Ovário , Fisiologia , Resultado da Gravidez , Taxa de Gravidez , Estudos Retrospectivos
11.
Chinese Journal of Biotechnology ; (12): 1281-1291, 2011.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-304576

RESUMO

We investigated the enhanced immune response of a recombinant T cell immunogen as an effective cellular immune adjuvant. The T cell immunogen named TI contained several T cell epitopes from the VP1, VP4, 3A and 3D proteins of foot-and-mouth disease virus (FMDV) and two pan-T helper (T(H)) cell sites to broaden the immunogenicity of the protein. Meanwhile, another fusion protein named OA-VP1 was expressed in bacteria, which contained two VP1 proteins of O and Asia1 type FMDV. Mice were vaccinated with commercially inactivated vaccine or OA-VP1 protein with or without the TI immunogen. The results show that mice inoculated with inactivated vaccine or OA-VP1 protein supplemented with TI immunogen produced significantly higher level of neutralizing antibodies (P < 0.01 or P < 0.05) than the mice only inoculated with inactivated vaccine or OA-VP1 protein by microneutralization assay. An obvious increase in T cell number by flow cytometric analysis and significantly higher concentration of IFN-gamma secreted in culture media of spleen lymphocytes were observed in groups supplemented with TI immunogen (P < 0.01). TI immunogen was an effective stimulator for humoral and cellular immunity and could help improve the immunogenicity of inactivated vaccine or protein subunit vaccine.


Assuntos
Animais , Camundongos , Adjuvantes Imunológicos , Farmacologia , Proteínas do Capsídeo , Genética , Alergia e Imunologia , Epitopos de Linfócito T , Genética , Alergia e Imunologia , Febre Aftosa , Alergia e Imunologia , Virologia , Vírus da Febre Aftosa , Alergia e Imunologia , Imunização , Vacinas Virais , Genética , Alergia e Imunologia , Farmacologia
12.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-276484

RESUMO

<p><b>OBJECTIVE</b>To study the distribution of human papillomavirus (HPV) subtypes in nasal inverted papilloma (NIP), and to evaluate the relationship between HPV and NIP.</p><p><b>METHODS</b>Twenty-one HPV subtypes were detected in paraffin-embedded tissues of 101 cases of NIP by flow through hybridization and gene chip (HybriMax), 24 cases of normal nasal mucosa were used as controls.</p><p><b>RESULTS</b>HPV positive rates of NIP were 64.36% (65/101). Benign NIP group, NIP with atypical hyperplasia group, NIP with cancerous group of HPV positive rates were 59.7% (46/77), 81.8% (18/22) and 50% (1/2) respectively. The control group was negative (0/24). The comparison between NIP group and control group was statistically significant (chi(2) = 32.178, P < 0.05). Benign NIP group and NIP with atypical hyperplasia group were compared, but no statistically significance (chi(2) = 3.649, P = 0.056) was found. The constituent ratio of benign NIP group and NIP with atypical hyperplasia group in high, low-risk HPV subtypes infections was compared, a statistically significance (chi(2) = 10.412, P < 0.05) was found.</p><p><b>CONCLUSIONS</b>The occurrence of NIP was related with HPV infection. High-risk HPV subtype infections or multiple infections will prompt benign NIP to NIP with atypical hyperplasia. Understanding the distribution of HPV subtypes in the NIP is helpful to predict the clinical behavior.</p>


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos de Casos e Controles , Neoplasias Nasais , Patologia , Virologia , Papiloma Invertido , Patologia , Virologia , Papillomaviridae , Classificação , Infecções por Papillomavirus , Patologia
13.
National Journal of Andrology ; (12): 305-309, 2010.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-295070

RESUMO

<p><b>OBJECTIVE</b>To evaluate the clinical application value of oocyte vitrification in failed testicular sperm extraction cycles in non-obstructive azoospermia (NOA) patients.</p><p><b>METHODS</b>We retrospectively analyzed the clinical data of 8 women undergoing oocyte frozen-thawing cycles by vitrification because of failed testicular sperm extraction from their NOA husbands and no banked donor sperm on the day of oocyte retrieval. The oocytes were cryopreserved by vitrification with cryotop and thawed 2 months later. The surviving metaphase II (MII) oocytes were injected with the banked donor sperm of the same blood type as the husbands by intracytoplasmic sperm injection (ICSI) for fertilization. The rates of oocyte survival, fertilization, cleavage, good embryos and pregnancy were evaluated.</p><p><b>RESULTS</b>Sixty oocytes were vitrified and 47 (78.3%) survived after thawing, of which 41 MII oocytes underwent ICSI and 33 (80.5%) of them were fertilized. The rates of cleavage and good embryos were 81.8% (27/33) and 59.3% (16/27) respectively. Fifteen of the embryos were transferred to the 8 patients, with 1.9 +/- 0.8 per cycle, of which 5 (33.3%) were confirmed by ultrasound to have been implanted and 5 resulted in clinical pregnancy (62.5%), all singleton without miscarriage. Three normal boys and 1 normal girl were already born, with the pregnancy time of (39 + 4 +/- 0.4) wk and newborn body weight of (3787.5 +/- 513.7) g, respectively.</p><p><b>CONCLUSION</b>Vitrification of oocytes in failed testicular sperm extraction cycles is a promising technique for preserving female fertility, which, with ICSI of banked donor sperm, may result in satisfactory clinical outcomes.</p>


Assuntos
Adulto , Feminino , Humanos , Masculino , Gravidez , Azoospermia , Criopreservação , Métodos , Oócitos , Taxa de Gravidez , Estudos Retrospectivos , Bancos de Esperma , Injeções de Esperma Intracitoplásmicas , Testículo , Falha de Tratamento
14.
National Journal of Andrology ; (12): 328-332, 2010.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-295065

RESUMO

<p><b>OBJECTIVE</b>To investigate the effects and clinical pregnancy outcomes of intracytoplasmic sperm insemination (ICSI) with microamount frozen-thawed sperm obtained by percutaneous epididymal sperm aspiration (PESA) or testicular sperm aspiration (TESA) in azoospermia patients.</p><p><b>METHODS</b>We divided 365 azoospermia patients treated by ICSI into an experimental group (n = 123) and a control group (n = 242) , the former with microamount frozen-thawed sperm, and the latter fresh sperm obtained by PESA or TESA. The rates of fertilization, good embryos, clinical pregnancy, miscarriage, ectopic pregnancy and multiple pregnancy were analyzed and compared between the two groups.</p><p><b>RESULTS</b>With PESA, the experimental group showed no statistically significant differences from the control group in the rates of fertilization (75.67% vs 76.49%), good embryos (64.96% vs 66.09%), clinical pregnancy (55.21% vs 57.22%), clinical miscarriage (13.21% vs 12.61%), ectopic pregnancy (3. 77% vs 5.41%) and multiple pregnancy (37.74% vs 37.84%) (P > 0.05); nor with TESA (74.41% vs 76.43%, 64.63% vs 66.35%, 46.81% vs 53.39%, 18.18% vs 14.55%, 4.55% vs 1.82%, 37.74% vs 37.84%, P > 0.05). The revival rate of the frozen-thawed sperm from PESA was 70.07%, not significantly different from that of TESA (62.67%) (P > 0.05).</p><p><b>CONCLUSION</b>ICSI with frozen-thawed micro-amount sperm obtained by PESA or TESA is a safe, economic and effective method for the treatment of azoospermia. The techniques for reviving frozen sperm from PESA or TESA remain to be optimized, and whether these techniques may result in long-term genetic risks in the offspring deserves further investigation.</p>


Assuntos
Adulto , Feminino , Humanos , Masculino , Gravidez , Azoospermia , Terapêutica , Oligospermia , Terapêutica , Taxa de Gravidez , Injeções de Esperma Intracitoplásmicas , Métodos , Recuperação Espermática
15.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-354984

RESUMO

Using the electron spin resonance (ESR) and probe technique, the species of reactive oxygen free radicals and the oxygen consumption were observed in the metabolic process of oxygen of leukocytes from leukemia patients and healthy persons. Results showed that weak ESR spectrum of hydroxyl radical ((*)OH) signal was detected in the leukemia patient's leukocytes, there was no significant difference in oxygen consumption with or without PMA stimulation; superoxide anion (O(2)) in normal leukocytes was detected, and oxygen consumption increased markedly compared to the normal respiration without PMA stimulation (P < 0.001). There was no significant difference in oxygen consumption between leukemic and normal leukocytes without PMA stimulation; however, it was higher in normal leukocyte than in leukemic leukoeytes after PMA stimulation (P < 0.001). These observations suggest that dysfunction of respiratory burst is existed in leukemic leukocytes, and their oxygen consumption is markedly lower than that of normal leukocytes.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...